Experimental doses in humans have ranged from 2-5mg administered twice weekly subcutaneously
Love the amount of energy these shots are giving me
Potential Benefits Skin wound healing: investigated for accelerated wound closure and organized skin repair through collagen synthesis, angiogenesis, and fibroblast activation Collagen and elastin production: copper-dependent lysyl oxidase activation in fibroblasts supports structural crosslinking of new connective tissue Anti-aging and anti-wrinkle: topical GHK-Cu and its palmitoyl derivative (Pal-GHK) are investigated for facial skin rejuvenation, wrinkle reduction, and skin firmness improvement Hair follicle stimulation: investigated for hair growth support through follicle reactivation and improved scalp vascularity Post-surgical wound recovery: skin and soft tissue repair following surgical procedures, particularly where collagen remodeling and scar minimization are clinical goals Anti-inflammatory: NF-kB pathway suppression and cytokine reduction at wound and injury sites, reducing the chronic inflammatory phase that impairs tissue repair GI mucosal healing: demonstrated in ulcerative colitis models through inhibition of the SIRT1/STAT3 signaling pathway, reducing inflammatory cytokines and promoting tight junction protein expression Antioxidant defense: activation of superoxide dismutase and catalase reduces oxidative stress and reactive oxygen species at sites of tissue damage Neuroprotective properties: preclinical research has investigated GHK-Cu for nerve regeneration support and gene expression changes relevant to neurological repair Combination synergy with BPC-157 and TB-500: GHK-Cu contributes copper-dependent enzyme activation and gene expression regulation to complement the VEGF angiogenesis of BPC-157 and the cell migration signaling of TB-500 in comprehensive wound healing protocols Speak with a physician Interested in GHK-Cu
People with sensitive skin or known copper allergies should use with caution
Researchers studying simultaneous fat loss and muscle preservation will recognize this as addressing the most common complaint about GLP-1 therapy
Cagrilintide is being studied for obesity and type 2 diabetes, with extensive data from both animal models and human clinical trials
